Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Wnt signaling pathway | R-HSA-195721 | map04310 | 3-aminobenzamide | 6505803 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | 3-aminobenzamide | 6505803 | drug-path |
p53 signaling pathway | R-HSA-168638 | map04115 | 3-aminobenzamide | 6505803 | drug-path |
Adherens junction | R-HSA-451386 | map04520 | bucladesine | 9687 | drug-path |
MAPK signaling pathway | R-HSA-9652817 | map04010 | bucladesine | 9687 | drug-path |
Colorectal cancer | R-HSA-4791275 | map05210 | bucladesine | 9687 | drug-path |
Chronic myeloid leukemia | R-HSA-9680350 | map05220 | bucladesine | 9687 | drug-path |
Glioma | Q9NZM4 | map05214 | bucladesine | 9687 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | bucladesine | 9687 | drug-path |
Renal cell carcinoma | R-HSA-9794523 | map05211 | bucladesine | 9687 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | bucladesine | 9687 | drug-path |
Huntington's disease | R-HSA-1643685 | 0 | bucladesine | 9687 | drug-path |
Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | bucladesine | 9687 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | bucladesine | 9687 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | bucladesine | 9687 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | bendroflumethiazide | 4534 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | bendroflumethiazide | 4534 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | bendroflumethiazide | 4534 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | bendroflumethiazide | 4534 | drug-path |
Axon guidance | R-HSA-422475 | map04360 | bendroflumethiazide | 4534 | drug-path |